MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Align Technology Deferred Revenue 2011-2026 | ALGN
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Align Technology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.33 B | 1.43 B | 1.34 B | 1.15 B | 778 M | 564 M | 406 M | 267 M | 191 M | 130 M | 90.7 M | 77.3 M | 62 M | 52.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 52.3 M | 562 M |
Quarterly Deferred Revenue Align Technology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 1.32 B | 1.32 B | 1.33 B | 1.38 B | 1.38 B | 1.41 B | 1.43 B | 1.41 B | 1.4 B | 1.38 B | 1.34 B | 1.29 B | - | 1.21 B | 1.15 B | 1.07 B | 976 M | 863 M | 778 M | 778 M | 778 M | 778 M | 564 M | 564 M | 564 M | 564 M | 393 M | 393 M | 393 M | 393 M | 268 M | 268 M | 268 M | 268 M | 191 M | 191 M | 191 M | 191 M | 130 M | 130 M | 130 M | 130 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 62 M | 62 M | 62 M | 62 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 52.3 M | 575 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | USA |
 |
AdaptHealth Corp.
AHCO
|
59.8 M | $ 13.38 | 2.29 % | $ 1.81 B | USA |
 |
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | USA |
 |
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | USA |
 |
EDAP TMS S.A.
EDAP
|
3.41 M | $ 3.28 | 1.86 % | $ 123 M |  France |
 |
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | USA |
 |
Globus Medical
GMED
|
27.7 M | $ 90.74 | -3.16 % | $ 12.3 B | USA |
 |
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | USA |
 |
Cytosorbents Corporation
CTSO
|
182 K | $ 0.6 | -1.96 % | $ 37.3 M | USA |
 |
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | USA |
 |
ClearPoint Neuro
CLPT
|
1.67 M | $ 11.08 | -1.16 % | $ 314 M | USA |
 |
Helius Medical Technologies
HSDT
|
148 K | $ 2.08 | -1.89 % | $ 1.26 M | USA |
 |
Eargo
EAR
|
621 K | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | USA |
 |
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | USA |
 |
LENSAR
LNSR
|
2.6 M | $ 5.35 | 2.69 % | $ 64 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
LivaNova PLC
LIVN
|
11.5 M | $ 61.29 | -3.34 % | $ 3.34 B |  Britain |
 |
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | USA |
 |
Pulmonx Corporation
LUNG
|
18 K | $ 1.23 | -4.3 % | $ 50 M | USA |
 |
Butterfly Network
BFLY
|
16.1 M | $ 5.16 | -5.84 % | $ 1.09 B | USA |
 |
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | USA |
 |
Delcath Systems
DCTH
|
170 K | $ 10.55 | -2.68 % | $ 378 M | USA |
 |
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.04 | -3.7 % | $ 17.6 M | USA |
 |
Sintx Technologies
SINT
|
4.72 K | $ 2.15 | -8.51 % | $ 5.96 M | USA |
 |
Integer Holdings Corporation
ITGR
|
5.21 M | $ 84.64 | -0.83 % | $ 2.94 B | USA |
 |
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | USA |